Doppler 2D has been deleted from recommendations 1.2.8, 1.2.9 and 1.2.11 because all transthoracic echocardiography would have doppler 2D as a minimum and it is no longer necessary to specify this. 'Multigated acquisition scanning' has been added to recommendation 1.2.11 to reflect current imaging technology. Measurement of urea has been deleted from recommendations 1.2.12, 1.4.8 and 1.7.1 because the guideline committee agreed that it is not needed and is not part of renal function profiles in most centres in the UK. Blood tests for electrolytes, creatinine and eGFR have been grouped together under the term 'renal function profile' because they are provided as a unified set of analyses in the NHS. The term 'profile' is applied to a group of tests (assays). Thus these tests are more accurately described as 'profiles' as they contain multiple individual assays and have replaced thyroid function test, liver function test and lipid measurement. 'Fasting glucose' has been replaced by 'glycosylated haemoglobin (HbA1c)' in line with the NICE guidelines on diabetes. Measurement of serum urea has been deleted from recommendation 1.4.4 because the guideline committee agreed that it is not needed and is not part of renal function profiles in most centres in the UK. Measurement of potassium has been added to ensure that monitoring is consistent across treatments. Recommendations 1.4.6 and 1.4.10 have been added to clarify the timing of monitoring after treatment starts. In recommendation 1.4.8, monitoring for hyperkalaemia has been replaced by potassium measurement for clarity. Blood pressure measurement has been clarified in recommendation 1.4.13 and made consistent with other treatments. 34 of As a result of new evidence the treatment pathway for heart failure with reduced ejection fraction in recommendation 1.4.26 has been amended. Second line treatment has been replaced by specialist treatment. 